Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights...
Stay updated with breaking news from Following Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights...
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global (ex-China)...
/PRNewswire/ -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for...
Press release content from Accesswire. The AP news staff was not involved in its creation.
Following Phase2b/SARA-INT clinically meaningful results, Biophytis is starting first regulatory activities to advance from Phase 2 to Phase 3 developmentA Type B/End-of-Phase 2 meeting is planned with